PLSE vs. ANIK, SRDX, NPCE, SKIN, TCMD, BVS, OSUR, GUTS, LYRA, and CVRX
Should you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include Anika Therapeutics (ANIK), Surmodics (SRDX), NeuroPace (NPCE), Beauty Health (SKIN), Tactile Systems Technology (TCMD), Bioventus (BVS), OraSure Technologies (OSUR), Fractyl Health (GUTS), Lyra Therapeutics (LYRA), and CVRx (CVRX). These companies are all part of the "surgical & medical instruments" industry.
Pulse Biosciences (NASDAQ:PLSE) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
Pulse Biosciences has a net margin of 0.00% compared to Anika Therapeutics' net margin of -49.60%. Anika Therapeutics' return on equity of -2.10% beat Pulse Biosciences' return on equity.
77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 69.7% of Pulse Biosciences shares are held by insiders. Comparatively, 5.9% of Anika Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Anika Therapeutics received 52 more outperform votes than Pulse Biosciences when rated by MarketBeat users. However, 65.17% of users gave Pulse Biosciences an outperform vote while only 64.30% of users gave Anika Therapeutics an outperform vote.
Pulse Biosciences has higher earnings, but lower revenue than Anika Therapeutics. Pulse Biosciences is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Anika Therapeutics had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.00 beat Anika Therapeutics' score of -0.26 indicating that Pulse Biosciences is being referred to more favorably in the media.
Anika Therapeutics has a consensus price target of $29.50, suggesting a potential upside of 15.37%. Given Anika Therapeutics' higher probable upside, analysts plainly believe Anika Therapeutics is more favorable than Pulse Biosciences.
Pulse Biosciences has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.
Summary
Anika Therapeutics beats Pulse Biosciences on 9 of the 17 factors compared between the two stocks.
Get Pulse Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulse Biosciences Competitors List
Related Companies and Tools
